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H3K9 methyltransferases and demethylases
control lung tumor-propagating cells and lung
cancer progression
1234567890():,;

S.P. Rowbotham1,2, F. Li3, A.F.M. Dost1,2, S.M. Louie1,2, B.P. Marsh1,2, P. Pessina1,2, C.R. Anbarasu 1,2,
C.F. Brainson4, S.J. Tuminello5, A. Lieberman6, S. Ryeom6, T.M. Schlaeger1, B.J. Aronow7, H. Watanabe5,
K.K. Wong3 & C.F. Kim1,2,8

Epigenetic regulators are attractive anticancer targets, but the promise of therapeutic strategies inhibiting some of these factors has not been proven in vivo or taken into account
tumor cell heterogeneity. Here we show that the histone methyltransferase G9a, reported to
be a therapeutic target in many cancers, is a suppressor of aggressive lung tumorpropagating cells (TPCs). Inhibition of G9a drives lung adenocarcinoma cells towards the
TPC phenotype by de-repressing genes which regulate the extracellular matrix. Depletion of
G9a during tumorigenesis enriches tumors in TPCs and accelerates disease progression
metastasis. Depleting histone demethylases represses G9a-regulated genes and TPC phenotypes. Demethylase inhibition impairs lung adenocarcinoma progression in vivo. Therefore,
inhibition of G9a is dangerous in certain cancer contexts, and targeting the histone demethylases is a more suitable approach for lung cancer treatment. Understanding cellular
context and speciﬁc tumor populations is critical when targeting epigenetic regulators in
cancer for future therapeutic development.
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T

umors are phenotypically heterogeneous, containing cells
with widely different disease-promoting potential. The
most aggressive cells exhibit regenerative and proliferative
behaviors associated with tissue progenitor cells and are often
referred to as cancer stem cells or tumor-propagating cells
(TPCs). We previously identiﬁed TPCs in the KrasLSL p53ﬂox/ﬂox
(hereafter referred as Kras;p53) mouse model of lung adenocarcinoma. Sca-1 (stem cell antigen-1, also Ly6a) and CD24
enriched for a population of cells with enhanced transplantation
efﬁciency1, and greater metastatic potential2. A combination of
CD24, ITGB4 (integrin β4), and high Notch receptor expression
has also been used to isolate TPCs from this model3. These
approaches have made it possible to investigate why TPCs behave
differently compared to other tumor cells.
Chromatin-modifying and/or chromatin-interacting proteins,
often referred to as epigenetic regulators, play essential roles in
delineating cell fate and governing the behavior of stem or progenitor cells. Epigenetic regulators are frequently ampliﬁed,
mutated, or mis-regulated in cancer, often playing important
roles in tumorigenesis, and have thus become the focus of an
entire ﬁeld of therapeutic discovery4,5. G9a and Glp (also Ehmt2
and Ehmt1, respectively) are histone methyltransferases (HMTs)
that catalyze the mono-methylation and di-methylation of histone H3 lysine 9 (H3K9). These enzymes are known for regulating embryonic stem cell differentiation, particularly into
neuronal lineages6,7, and have also been linked to cancer, where
G9a is mutated or ampliﬁed at a low frequency in a variety of
tumors8. The majority of studies describe G9a as an oncogene,
ﬁnding
G9a
to
have
pro-proliferative
and
proepithelial–mesenchymal transition (pro-EMT) functions9–12.
These results have spurred the development of chemical inhibitors of G9a/Glp in the hope that they could be used as anticancer
therapeutics13–15. Chromatin modiﬁcations are dynamically
regulated, and multiple lysine demethylases (KDMs) can remove
H3K9 methylation, including Kdm3a (also Jmjd1a, JHDM2a) and
Phf816,17. These enzymes have been linked to tumorigenesis and
stem cell behavior in other tissues18–20, making them plausible
candidates to regulate these phenotypes in the lung. However, a
speciﬁc role for H3K9 methylation regulators in progenitor cell
behavior in lung cancer has not been explored.
By screening for regulators of TPC surface markers, we identify
the H3K9me1/2 HMTs G9a and Glp as TPC suppressors;
depleting G9a during tumorigenesis expands the TPC population
and accelerates disease progression. Inhibiting or depleting G9a
upregulates genes associated with mutant KRAS and extracellular
matrix (ECM) regulation, and depleting these genes or overexpressing G9a impedes tumor transplantation. Depleting or
inhibiting H3K9me1/2 KDMs impairs the TPC phenotype,
revealing this a possible means to further develop a lung adenocarcinoma therapeutic.
Results
G9a/Glp inhibition drives cells towards the TPC phenotype. To
determine which molecular pathways regulate lung adenocarcinoma TPCs, we tested a library of stem cell-regulating small
molecules (Table 1). We screened a TPC-like cell line, CK17502, for
changes in the surface antigens Sca-1 and CD24, reasoning that
changes in these markers could correspond to changes in TPC
activity. Multiple compounds increased the levels of at least one
TPC antigen (Fig. 1a, Supplementary Fig. 1a), and we focused on
characterizing the effect of the molecule that increased Sca-1 the
most signiﬁcantly (1.8-fold vs. dimethyl sulfoxide (DMSO), P =
0.0015, t test), UNC0638. UNC0638, a potent speciﬁc inhibitor of
the H3K9 mono-methyltransferase and di-methyltransferases Glp
and G9a21, increased Sca-1 in multiple adenocarcinoma cell lines,
2

with a greater difference in lines with low endogenous Sca-1 levels,
TM1 and TnM2 (Fig. 1b, Supplementary Fig. 1b). UNC0638 also
increased Sca-1 mRNA (2.1-fold, P = 0.036, 19.8-fold, P = 0.0005,
and 104.3-fold, P = 0.0001, t test), implying that higher Sca-1 levels
were due to upregulated transcription (Fig. 1c).
We have previously demonstrated that CD24 and Sca-1 mark a
population enriched in TPCs1,2. To further explore the effects of
G9a/Glp inhibition (hereafter referred as G9ai) on tumorpropagating ability, we modeled this phenotype with primary
adenocarcinoma cells in Matrigel air–liquid interface cultures.
Sca-1+CD24+ cells formed organoids at a higher rate than other
primary tumor populations (5.8 vs. 3.1, 3.3, and 1.9%, P = 0.002,
P = 0.0007, P = 0.0002, t test), demonstrating that more efﬁcient
in vitro organoid formation correlates with a TPC-enriched
population (Supplementary Fig. 1c). G9ai of Sca-1-low adenocarcinoma cell lines increased the proportion of Sca-1-expressing
cells and led to increased organoid-forming efﬁciency (3.95 vs.
0.75%, P = 0.004 and 6.1 vs. 2.7%, P = 0.025, t test) (Fig. 1d).
G9ai of unsorted primary adenocarcinoma cells in 3D culture also
increased organoid formation (0.97 vs. 0.25%, P = 0.027, 1.32 vs.
0.29%, P = 0.03, t test) (Fig. 1e) and resulted in more Sca-1+ cells
when cultures were analyzed at the experimental endpoint
(Supplementary Fig. 1d). To further demonstrate that G9ai could
promote a TPC phenotype, we inhibited Sca-1-low adenocarcinoma cell lines and intravenously injected them into immunocompromised (nude) recipient mice (Fig. 1f, Supplementary
Fig. 2a). At the experimental endpoint, we detected lung tumors
in the recipients of both G9ai and vehicle control-treated cells
(Fig. 1f, Supplementary Fig. 2b). However, mice that had received
G9ai cells more frequently presented with tumors outside the
lung (thoracic lymph nodes, aorta, subcutaneous) (58 vs. 17%,
P = 0.017, Fisher’s exact test) (Fig. 1f, Supplementary Fig. 2b),
demonstrating that G9ai can also promote a more tumorigenic
TPC phenotype in vivo.
Our ﬁndings that lower G9a and H3K9me2 were associated
with TPCs and that G9ai can increase the tumorigenicity of
cancer cells appeared to contrast with other studies, suggesting
that G9a is oncogenic9–12. Although 1 µM UNC0638 (the
concentration used in our assays) did not affect cell proliferation
or survival (Supplementary Fig. 2c, d), higher concentrations (5
and 10 µM) resulted in signiﬁcant decreases (optical density (OD)
600 1.16 vs. 0.74, 0.09, P = 0.002, <0.001, t test, Supplementary
Fig. 2d). This was in line with previous ﬁndings describing G9 as
a pro-proliferative10,12, and shows how without considering
cellular context and tumor heterogeneity, G9ai could be
considered as a potential anti-oncogenic treatment.
As enzymatic inhibition of G9a/Glp could promote TPC
characteristics in adenocarcinoma cells, we hypothesized that less
G9a/Glp or deregulated H3K9me1/2 could be an intrinsic TPC
property. Re-analysis of our previous gene expression data
comparing Kras;p53 TPCs vs. non-TPCs2 indicated that G9a, but
not Glp, was signiﬁcantly downregulated in the TPC-enriched
population (0.41-fold, P = 0.037, t test) (Fig. 1g), suggesting that
reduced G9a levels may be important to lung TPCs. To conﬁrm this
association, we stained global H3K9me2 and Sca-1 in sorted lung
adenocarcinoma populations. We found that global H3K9me2 was
signiﬁcantly higher in the least tumorigenic, Sca-1−CD24− cell
population than in the CD24+Sca-1-, CD24-Sca-1+ and CD24
+Sca-1+ populations (36.3 ﬂuorescent units vs. 6.4, 4.8, 6.2, P =
0.004, P = 0.003, and P = 0.004, t test), while Sca-1 was signiﬁcantly
higher in the Sca-1+CD24+ population compared to all the others
(89.5 vs. 14.0, 9.6, 33.4, P = 0.003, P = 0.003, and P = 0.013, t test)
(Fig. 1h, i). These data show an inverse association between Sca-1,
TPC, and H3K9me2, suggesting that H3K9 demethylation may be a
feature of, or a prerequisite for, lung adenocarcinoma TPCs and
tumor progression and metastasis.
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Table 1 Composition of the Stem Cell Chemical Library used for screening lung adenocarcinoma TPCs
Compound
CCPA
SQ22536
Forskolin
SR1
ITE
ABT 702
dihydrochloride
KP372-1
(+)-JQ1- 1 mg
Dorsomorphin
CITCO
Indomethacin
AMD3100
FCCP
A77 1726
RG 108
5-Aza-2′deoxycytidine
5-Azacytidine
SGC 0946
AG 1478
Erlotinib
GSK126
PF 573228
PD161570
UNC 0638
Dexamethasone
Depudecin
Sodium butyrate
Trichostatin A
Valproic acid
GANT 61
Purmorphamine
20(S)Hydroxycholesterol
IOX2
IKK16
Revstarol
cp690550
Tranylcypromine
HCl
PD98059
Nutlin
PD0325901
Rapamycin
Honokiol
Betulinic acid
SNAP
DETA NONOate
L-NAME

Mechanism
A1+
Acase−
Acase+
ahr−
AHR+
AK−

Compound
Compound W
DAPT
DLPC
2-Phospho-L-ascorbic acid
IPA-3
EB-47

Mechanism
Notch
Notch
nr2a5
P
Pak−
parp1−

AKT−
BET−
bmpr−
CAR
cox
cxcr4−
decoupl
dhodh
DNMT
DNMT−

DMPQ dihydrochloride
SU6656
Mycophenolate mofetil
PS48
16,16-Dimethyl prostaglandin E2
GDC-0941
PI-103
cAMPS-Rp
GSK 0660
BADGE

pdgf r inh
pdgf/fgf/vegf r inh
PDH2
PDK1
PGE2
pi3k
pi3k− mtor− dnapk−
PKA−
PPARd−
pparg−

DNMT1−
DOT1L−
EGFR
egfr−
EZH2−
FAK
fgfr−
g9a inh
gc
HDAC−
HDAC−
HDAC−
HDAC−
HH−
HH+
HH+

GW9662
Troglitazone
AM 114
NSC 23766
BMS 493
BMS195614
AM580
AC 261066
CD2665
BMS 961
y27632
Blebbistatin
BI-D1870
W146
SEW2871
Splitomycin

PPARg−
pparg+
Proteasome
RAC
RAR+
RARa−
RARa+
RARb+
RARbg−
RARg+
rock−
rock/mlck
RSK
s1p1−
s1p1+
sirp2−

HIF+
IKK
jak 3/2/1 inh
jak−
LSD1−

ex527
agk2
A83-01
repsox
IDE-1

sirt1−
sirt2−
tgfb−
tgfb− alk5−
TGFb+

MAPK
mdm2 inh
MEK
mtor
nfkb−
nfkb+
NO
NO+
NOS−

SB431542
TLR3/dsRNA complex inhibitor
MLS000389544
1–850
3,3′,5-Triiodo-L-thyronine sodium salt
RN 1734
ZM 306416 hydrochloride
IWP-2
XAV 939
CHIR99021

tgfb1
tlr3 inh
TR−
TR+
TR+
TRP channels
vegf r inh
wnt−
Wnt−
wnt+gsk−

G9a depletion promotes tumor progression and metastasis.
Historically, TPCs have largely been studied ex vivo using surface
markers and transplantation experiments. Identiﬁcation of G9a as
a TPC-regulating enzyme allowed us to test its function, and the
role of TPCs more broadly, in tumorigenesis in situ. We utilized
bi-functional Cre-U6shRNA lentiviral vectors to knockdown G9a
only in the induced tumors of Kras;p53 recipient mice (Fig. 2a,
Supplementary Fig. 3a). At the experimental endpoint, recipients
of shG9a lentivirus had remarkably progressed disease compared
to shLuciferase controls, with signiﬁcantly increased tumor
number (P = 0.0005, t test) and tumor burden (Fig. 2b, Supplementary Fig. 3b). Histological examination of tumors revealed
that shG9a recipients had signiﬁcantly advanced disease (P <
0.0001, χ2 test), with the majority of mice presenting aggressive,

poorly differentiated, grade 4 tumors, while the majority of
control mice had only grade 2 tumors (Fig. 2c, Supplementary
Fig. 3c). Quantitative PCR (qPCR) of isolated tumor cells and
immunostains of lung tumor sections from these mice conﬁrmed
that G9a was signiﬁcantly depleted in shG9a recipient tumors
compared to controls (Supplementary Fig. 3d, e). Although we
sacriﬁced mice in the same time frame for comparison, shG9a
mice grew sicker more quickly than controls (P = 0.017,
Mantel–Cox log-rank test), suggesting that G9a depletion was not
simply selecting for escaped, more aggressive tumor cells (Supplementary Fig. 3f). Proliferation was not altered in endpoint
shG9a tumors; similar proportions of cells stained for Ki67 in
shG9a and control tumors (21.1 vs. 14.6%, P = 0.45, t test)
(Supplementary Fig. 4a, b).
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Further analysis of shG9a Kras;p53 mice supported our
prediction that shG9a would correlate with more metastasis, as
we previously found that CD24+Sca-1+ cells give rise to
signiﬁcantly more metastases after orthotopic transplantation
compared to other tumor cell populations2. Indeed, metastases
were observed in the thoracic pleura and lymph nodes in a
signiﬁcantly higher proportion of shG9a Kras;p53 primary mice
compared to controls (50 vs. 0%, P = 0.0003 and 25 vs. 0%, P =
0.0265, Fisher’s exact test, Fig. 2d). Furthermore, ﬂuorescenceactivated cell sorting (FACS) of metastases from shG9a Kras;p53
mice or Kras;p53 mice with tumors initiated with Adeno-Cre
revealed that they almost entirely consisted of CD24+Sca-1+
4
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3
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CK1750 adenocarcinoma cells

TPCs (Supplementary Fig. 4c–e). Together, the data suggest that
G9a depletion can drive lung adenocarcinoma progression and
promote metastasis.
G9a depletion expands the TPC population in vivo. FACS
analysis of dissociated tumors revealed differences in the subpopulations of shG9a and control tumors. We found a 1.8-fold
signiﬁcant increase in the CD24+Sca-1+ cell population, previously shown to be enriched in TPCs2, in shG9a tumors (27.7 vs.
15.6%, P = 0.0185, Mann–Whitney test) and a corresponding
decrease in the proportion of CD24−Sca-1− cells (28 vs. 18.2%)
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Fig. 1 G9a/Glp inhibition drives cells towards the TPC phenotype. a Scatter plot of fold change in median ﬂuorescence of drug-screened CK1750 cells
labeled with ﬂuorescent anti-CD24 and anti-Sca-1 antibodies. Each point represents an individual compound, red = UNC0638, blue = other compounds.
b Representative (n = 5) FACS histogram of Sca-1 ﬂuorescence of lung adenocarcinoma cells following 96 h. treatment with 1 µM UNC0638 or vehicle
control, gated for live single cells. c qPCR of Sca-1 mRNA normalized to Gapdh from adenocarcinoma cells following 96 h. treatment with 1 µM UNC0638 or
vehicle control. Error bars denote standard deviation. *P < 0.05, t test, n = 3. d Bar chart of % of cells forming organoids 10 days after 1000
adenocarcinoma cells were plated in 3D culture with 1 µM UNC0638 or DMSO following 96 h. pre-treatment with UNC0638 or DMSO control. Error bars
denote standard deviation. *P < 0.05, t test, n = 3. e Representative bar chart of % of cells forming organoids 10 days after 5000 single cells isolated from a
primary adenocarcinoma were plated in 3D culture with 1 µM UNC0638 or DMSO. Error bars denote standard deviation. *P < 0.05, t test, n = 3 technical
replicates. f Experimental design of G9ai in intravenous transplantation assay, and table of tumor incidence in recipients of UNC0638-treated or DMSOtreated adenocarcinoma cells by intravenous injection. *P < 0.05, Fisher’s exact test. g Bar chart of mRNA abundance of G9a and Glp normalized to β-Actin
in Sca-1+ cells (TPCs) relative to Sca-1− cells (non-TPCs) from FACS-sorted primary adenocarcinomas, gated for single, live, CD31−, CD45− cells. Error
bars denote standard deviation. *P < 0.05, t test, n = 3. h Representative (n = 3) images of isolated lung adenocarcinoma cells sorted by CD24 and Sca-1,
gated for live, single, CD31−, CD45−, Epcam+ cells after cytospin and immunostained for the indicated markers. Scale bar = 20 µm. i Quantiﬁcation of
H3K9me2 and Sca-1 immunostaining of isolated lung adenocarcinoma cells sorted by CD24 and Sca-1, gated for live, single CD31−, CD45−, Epcam+ cells.
Error bars denote standard deviation. *P < 0.05, t test, n = 3

(Fig. 2e, f), reinforcing our hypothesis of G9a as a negative regulator of lung TPCs. It has also been previously reported that
Notch3 is enriched in lung TPCs and is required for lung TPC
function3. In line with these ﬁndings, we observed a signiﬁcant
increase in tumors with nuclear Notch3 localization in shG9a vs.
shLuc recipients and in mice receiving high titer Cre-Adenovirus,
which display more grade 3 and grade 4 tumors than shLuc
lentivirus controls (49 vs. 10%, P = 0.001, 26%, P = 0.008,
Mann–Whitney test) (Supplementary Fig. 4f, g).
In orthotopic transplantation experiments, recipients of shG9a
cells more frequently developed lung tumors and metastases (71
vs. 9%, P = 0.0095, 43 vs. 0%, P = 0.043, Fisher’s exact test)
compared to mice that received control Kras;p53 cells, further
conﬁrming that shG9a tumors have enriched TPC (Fig. 2g). To
show that G9a could directly increase the frequency of TPCs, we
used G9ai on wild-type lung adenocarcinoma cells and performed
limiting dilution transplantation assays. G9ai cells initiated more
tumors at higher dilutions than controls, increasing the estimated
TPC frequency (1/14 vs. 1/53, P = 0.0312, χ2 test) (Fig. 2h). These
results suggest that G9a loss drives lung adenocarcinoma
progression and metastasis by increasing the proportion of TPCs
within the tumor.
G9a controls TPCs through KRAS-associated and ECMassociated genes. To understand how G9 controls TPC
phenotypes, we sought to identify genes that acutely respond
to changes in G9a by using G9ai and H3K9me2
chromatin immunoprecipitation-sequencing (ChIP-seq) and
RNA-sequencing (RNA-seq). As has been observed with other
cells, we found that H3K9me covered large, Mb-sized genomic
domains22,23. We did not observe changes in the locations of
these domains (Supplementary Fig. 5a), even though global
H3K9me2 levels were signiﬁcantly reduced (Supplementary
Fig. 5b), suggesting that G9ai reduced H3K9me2 evenly across the
genome. RNA-seq however identiﬁed many genes differentially
expressed by G9ai (Supplementary Fig. 5c). ChIP-seq showed
lower H3K9me2 across the transcription starting sites (TSS) of
the RNA-seq genes commonly upregulated across multiple cell
lines, and higher H3K9me2 at the commonly downregulated
genes (Supplementary Fig. 5d).
Gene ontology enrichment analysis revealed that the commonly upregulated genes were most signiﬁcantly enriched in
signatures associated with expression of oncogenic KRAS, as well
as genes in signatures associated with the ECM, cellular secretion,
and the extracellular space (Fig. 3a, Supplementary Fig. 5e).
Additionally, the genes enriched within these terms were amongst
the individual most upregulated genes, and several genes were
present in both the KRAS-associated and ECM terms

(Supplementary Fig. 5e). We narrowed our focus to the most
signiﬁcantly upregulated genes enriched in the KRAS-associated
and ECM terms as candidates to mediate the TPC phenotype. We
conﬁrmed the signiﬁcant upregulation of multiple genes upon
G9ai by qPCR across multiple adenocarcinoma cell lines (Fig. 3b,
Supplementary Fig. 5f). To conﬁrm that these genes were also
regulated by G9a in vivo, we stained sections of control and
shG9a tumors. Matrix metalloproteases 10 and 13 (Mmp10 and
Mmp13) were expressed in shG9a metastases and in shG9a
primary tumors, but were absent in control tumors (Fig. 3c,
Supplementary Fig. 6a). We also conﬁrmed by qPCR that a subset
of these genes (Anxa10, Ctse, Mmp10, Mmp13, Lcp1) were
consistently upregulated in shG9a tumor cells compared to
controls (Supplementary Fig. 6b).
Of these genes, Mmp10 was the highest ranked gene enriched
in both the KRAS-associated and ECM gene signatures.
Interestingly, Mmp10 has previously been reported as required
for lung stem cell expansion as well as lung adenocarcinoma
initiation and metastasis24,25, making it a logical candidate to
mediate the TPC phenotypes regulated by G9a. We depleted
Mmp10 from cell lines derived from shG9a tumors with shRNA
hairpins (Supplementary Fig. 6c) and compared their tumorforming efﬁciency with shGFP controls. Depletion of Mmp10 in
the shG9a background signiﬁcantly reduced tumor burden
following intravenous transplantation (38.3 vs. 3.9%, P < 0.0001,
t test) (Fig. 3d), implying that Mmp10 functions in the TPC
phenotype. Furthermore, ChIP-PCR showed that H3K9me2 was
signiﬁcantly depleted by G9ai at the TSSs of Mmp10 as well as
Sca-1 (P = 0.004, P = 000.5, t test) (Fig. 3e), suggesting that
transcription of these genes was directly regulated by G9a.
To conﬁrm that G9a controlled the TPC phenotype by
suppressing KRAS-associated and ECM-regulating genes, we
rescued G9a expression in SR0144 cells derived from shG9a
tumors. Expression of human G9a increased global H3K9me2
compared to Cre-expressing controls (Supplementary Fig. 6d, e).
G9a rescue signiﬁcantly repressed G9a-regulated genes Sca-1 and
Mmp10 (0.03-fold, P = 0.0003 and 0.0008-fold, P < 0.0001, t test)
(Fig. 3f), lowered Sca-1 surface protein levels (Supplementary Fig.
6f), and signiﬁcantly reduced Mmp enzymatic activity (0.69-fold,
P = 0.0082, t test) (Supplementary Fig. 6g). Following intravenous
transplantation, G9a-rescued cells generated a signiﬁcantly lower
lung tumor burden than controls (9.4 vs. 31.9%, P = 0.016, t test)
(Fig. 3g), reinforcing the conclusion that G9a directly regulates
TPC tumorigenicity. As G9a represses Mmp10 and other secreted
proteases, we asked if G9a could regulate how tumor cells interact
with the ECM. When we cultured cells in invasion assays, where
serum-starved cells must migrate through a 3D matrix barrier
towards serum-rich media, G9a-depleted cells showed
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signiﬁcantly more invasion than controls expressing G9a (0.69fold, P = 0.0002, t test) (Fig. 3h). There was no difference between
cells in a matrix-free migration assay (Supplementary Fig. 6h),
suggesting that G9a activity more speciﬁcally regulates genes that
impact the ability of cells to manipulate the matrix. In total, these
data support the conclusion that one way by which G9a
suppresses TPC activity is by repression of Mmp10, which in
turn inﬂuences the ability to degrade the ECM.
Antagonizing H3K9 KDMs represses TPC phenotypes. G9a/Glp
are not commonly mutated in lung adenocarcinoma26; therefore,
we analyzed G9a and Glp expression in the Directors Challenge
data set from over 400 adenocarcinoma patients to determine if
G9a may be linked to clinical criteria in patients. Glp expression
was not predictive of outcome (Supplementary Fig. 7a), yet higher
G9a expression was correlated with signiﬁcantly better 10-year
6

survival (P = 0.0075, Mantel–Cox log-rank test) (Fig. 4a), as we
would predict if G9a functioned as we have shown in the mouse.
Interestingly, this contrasts with some previous studies, which
have suggested that G9a overexpression is associated with worse
clinical outcome9,27. As chromatin modiﬁcations are bidirectionally regulated, we looked to see if any H3K9me1/2
KDMs were also predictive of clinical outcome. We found one
H3K9 KDM, KDM3A (also JMJD1A, JHDM2A) for which high
expression correlated with worse 10-year survival (P = 0.0022,
Mantel–Cox log-rank test) (Fig. 4b), consistent with our
hypothesis that lower H3K9me1/2 promotes a TPC phenotype
and accelerated disease. To test if antagonizing an H3K9me1/2
KDM might impair TPC phenotypes and improve outcome, we
depleted Kdm3a in CK1750 mouse adenocarcinoma cells (Supplementary Fig. 7b). We observed that shKdm3a cells displayed
lower organoid-forming efﬁciency than control shGFP cells in 3D
culture (Fig. 4c), despite their proliferation rate in adherent
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culture being comparable to controls (Supplementary Fig. 7c).
When shKdm3a cells were transplanted into mice, signiﬁcantly
fewer lung and extra-lung tumors formed compared to control
cells (Fig. 4d, e), suggesting that the TPC properties of these cells
were also impaired. Similarly to rescued shG9a adenocarcinoma

cells (Fig. 3f), we observed signiﬁcant downregulation of the G9a
targets Sca-1 and Mmp10 (Fig. 4f), suggesting that Kdm3a
depletion may impede TPCs through the same mechanisms as
G9a expression in lung adenocarcinoma cells. When we returned
to our primary mouse adenocarcinoma data, we found that a
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different H3K9me1/2 demethylase, Phf8, was signiﬁcantly upregulated in Sca-1+ TPCs (3.6-fold, P = 0.022, t test) (Supplementary Fig. 7d). We also depleted Phf8 in CK1750 cells
(Supplementary Fig. 7e, f), and found that similarly shPhf8 cells
had a lower organoid-forming efﬁciency (Supplementary Fig. 7g),
formed fewer tumors when transplanted (Supplementary Fig. 7h),
and had reduced Sca-1 and Mmp10 expression (Supplementary
Fig. 7i).
Currently, there are no inhibitors that speciﬁcally target
Kdm3a or Phf8; however, there are several broad-spectrum
KDM inhibitors, which will inhibit these enzymes along with
other KDMs. We found that pan-jumonji inhibitor JIB-0428
increased H3K9me2 levels (Fig. 4g), and also resulted in the loss
of surface Sca-1 in adenocarcinoma cells (Supplementary Fig. 7j).
Furthermore, JIB-04 affected the viability of both mouse and
human adenocarcinoma and squamous non-small-cell lung
cancer (NSCLC) cell lines. JIB-04 had an approximately equal
or lower half-maximal inhibitory concentration (IC50) in both
mouse and human cell lines than Pemetrexed, a current frontline
therapeutic for the treatment of NSCLC (34.71 vs 180.6 nM, 67.68
vs 260.9 nM, Fig. 4h). We also performed allograft transplantations of adenocarcinoma cells into immunologically competent
host mice and treated them with either vehicle or JIB-04. After
7 weeks, relative tumor volume was signiﬁcantly higher in the
vehicle cohort compared to JIB-04-treated mice (271.35 vs. 56.7
mm3, P = 0.0014, t test) (Fig. 4i, j), suggesting that targeting TPCs
through H3K9me KDM inhibition could be an effective therapy
for lung adenocarcinoma.
Discussion
We found that inhibition of G9a, an HMT previously reported to
have oncogenic activity, leads to enhanced TPC function and
drives metastatic tumor progression. In vitro and in vivo studies
revealed that G9a represses a gene signature highly associated
with mutant KRAS-regulating and ECM-regulating genes,
including Mmp10, which partially mediates the tumorigenicity of
G9a-depleted tumor cells. Conversely, we found that inhibition of
H3K9 KDMs (KDMi) may be a beneﬁcial treatment for advanced
lung adenocarcinoma. By studying the epigenetic dependencies of

TPCs that represent a minority of tumor cells, our work has
revealed a potential new therapeutic intervention for advanced
lung cancer (Fig. 5).
Since the discovery of potent G9a/Glp inhibitors, there has
been an increase in studies investigating these enzymes in cancer.
Indeed, much of the rationale for developing G9a/Glp inhibitors
was that many tumors stained positively for these enzymes and
this was often correlated with worse outcome14,15,29. It has been
observed amongst almost all cancer models tested that G9a
inhibition has antiproliferative effects, and different mechanisms
have been proposed9,10. While we found that high concentrations
of G9a inhibitors were antiproliferative, we also observed that
G9a is downregulated in highly tumorigenic TPCs (and in an
H3K9 KDM, Phf8 is upregulated), coinciding with a signiﬁcant
reduction in global H3K9me2. Our data suggest that downregulation of G9a promotes TPCs, leading to disease progression,
metastasis, and worse clinical outcome, thus raising caution for
the use of G9a inhibitors, particularly for lung cancer treatment.
Our studies suggest that TPCs can promote tumorigenesis and
metastasis by inﬂuencing the extracellular environment. While
our data are consistent with previous studies which found that
deleting or inhibiting G9a can increase stem cell or tumor stemlike populations and oppose tissue-speciﬁc differentiation23,30, we
focused this study on the role of G9a in regulation of genes
affecting ECM. Mmp10, the G9a target we characterized in lung
cancer cells, directly mediates TPC tumorigenicity. In addition to
degrading the ECM to facilitate invasion, Mmp10 has also been
proposed to promote metastasis by proteolytically regulating
extracellular pools of growth factors such as TGF-β and
Wnt24,25,31,32. While at this stage we cannot rule out an Mmp10
effect on these signaling pathways, we favor the hypothesis that
Mmp10 expressed by lung TPCs acts on the ECM, as we observed
that G9a-overexpressing cells repress Mmp10, have lower Mmp
enzymatic activity, and are partially impaired in invading through
a 3D matrix. It has been hypothesized that the tumor microenvironment inﬂuences TPCs, but the ability of TPCs to alter
their surroundings via ECM remodeling warrants further study.
Mmps are strongly associated with poor survival in lung cancer,
but to date trials of Mmp inhibitors have not proven successful,
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through the lack of efﬁcacy, toxicity, or poor bioavailability33. We
found that Mmp10 is de-repressed by H3K9 KDMs; therefore,
KDMi may prevent or delay the re-expression of these genes,
potentially providing another angle to target Mmps in lung cancer.
Other studies have also found that KDMs are upregulated in cancers and this correlates with worse outcome28,34. This further
suggests that KDMi could be a useful therapeutic intervention,
particularly as chemoresistance is a proposed TPC trait35. JIB-04 is
a nonspeciﬁc KDM inhibitor and it is unlikely that all the effects we
observe are due to its inhibition of H3K9 KDMs. While several
more speciﬁc KDM inhibitors exist36,37, there are none that inhibit
all the H3K9me KDMs. The development of pan H3K9me KDM
inhibitors would be of great interest and potentially therapeutic
beneﬁt for highly refractive diseases such as lung adenocarcinoma.
As KRAS mutations are common, but KRAS itself is not a druggable target, our ﬁnding that H3K9 KDMi decreases expression of
genes associated with oncogenic KRAS suggests that H3K9 KDMi
represents a viable personalized therapy for patients with KRASmutated adenocarcinoma.
This study has highlighted the importance of choosing the best
model of cellular heterogeneity for analyses that may lead to new
therapeutic approaches in cancer. Studies primarily based on cell
lines or whole tumors have suggested that G9a is oncogenic and a
good target for epigenetic therapy, but our approach, beginning
with analyzing different tumor populations, led to a startlingly
different conclusion. We propose that analyzing the effects of new
therapeutics on different tumor populations, especially the most
tumorigenic stem-like cells, would be greatly beneﬁcial. This may
increase the success rate of clinical trials and thus reduce the cost
and time taken to bring new cancer therapeutics to the patient.
Methods
Cell lines. Mouse cell lines CK1750, SC241, and SR0144 were generated as previously described2. Cell lines TM1 and TnM2 were previously provided by Monte
Winslow. Mouse cell lines were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) + 10% fetal bovine serum (FBS), 4mM L-glutamine, and penicillin/
streptomycin at 37 °C with 5% CO2. Human H23 cells (ATCC CRL-5800) were
used as previously described38, cultured in RPMI-1640 media with 10% FBS, 4mM
L-glutamine, and 50 U/ml penicillin/streptomycin at 37 °C with 5% CO2.
Vectors. The pLKO.1 Mmp10, Kdm3a and Phf8 shRNA construct clones
TRCN000031240, TRCN000031241, TRCN0000252743, TRCN0000252745,
TRCN0000086826and TRCN0000086827 were purchased from Sigma and the
shGFP plasmid 12273 was available from Addgene38. The G9a expression vector39
41721 and Cre expression control vector40 34565 were also purchased from
Addgene. The shRNA EHMT2 (G9A) lentiviral vectors were created by cloning
hairpin oligonucleotides into the U6shRNA pgkCre backbone, created by the Tyler
Jacks lab and available from Addgene as previously described41. The vectors used
were as follows: shLuciferase—FWD, 5′-5Phos/TGA GCT GTT TCT GAG GAG
CCT TCA AGA GAG GCT CCT CAG AAA CAG CTC TTT TTT C-3′ and REV,
5′-5Phos/CGA GAA AAA AGA GCT GTT TCT GAG GAG CCT CTC TTG AAG
GCT CCT CAG AAA CAG CTC A-3′; shEHMT2 1—FWD, 5′-5Phos/TGG CTG
CTC CAG GAG TTT AAT TCA AGA GAT TAA ACT CCT GGA GCA GCC TTT
TTT C-3′ and REV, 5′-5Phos/TCG AGA AAA AAG GCT GCT CCA GGA GTT
TAA TCT CTT GAA TTA AAC TCC TGG AGC AGC CA-3′; shEHMT2 2—
FWD, 5′-5Phos/TGG AAG AGG AGG AAG AAG AAT TCA AGA GAT TCT
TCT TCC TCC TCT TCC TTT TTT C-3′ and REV, 5′-5Phos/TCG AGA AAA
AAG GAA GAG GAG GAA GAA GAA TCT CTT GAA TTC TTC TTC CTC
CTC TTC CA-3′.
Generation, concentration, and infection of mice with lentivirus was performed
as previously described42.

Chemical compounds. The Stem Cell Chemical Library was assembled from
commercially available compounds, and diluted to a stock of 10 mM in DMSO.
Chemicals were further diluted to 20 µM in DMEM before being added to the cells.
The chemicals used are listed in Table 1. UNC0638 was purchased from Cayman
Chemical and diluted to a stock of 10 mM in DMSO for all cell culture experiments. JIB-04 was purchased from Tocris was diluted to a stock of 10 mM in
DMSO for cell culture experiments and 5.5 mg/ml in Koliphor-EL (Sigma) for
mouse experiments. Pemetrexed was purchased from the Dana Faber Cancer
Center and was diluted to a stock of 100 mM in ddH2O. For cell culture
10

experiments, cells were grown in the presence of the drug for 96 h with fresh media
and drugs were supplied at 48 h.
Flow cytometry of in vitro cultured cells. For ﬂow cytometry screening, CK1750
cells were plated at 300 cells/well in 96-well plates and treated with compounds
from the Chemical Library for 96 h. For routine ﬂow cytometry analysis, cells were
grown and cultured as described above. Cells were then dissociated, washed, and
re-suspended in 2% FBS in phosphate-buffered saline (PBS) (PF2) and stained with
anti-CD24-PE (BD Pharmingen 553262, 1:100), anti-Sca-1-APC-Cy7 (BD Pharmingen 560654, 1:100), and DAPI (4′,6-diamidino-2-phenylindole) for 15 min on
ice. Cells were washed again and re-suspended in 50 mM EDTA, 2% FBS in PBS,
ﬁltered (40 µM), and sorted on a BD LSR II ﬂow cytometer. Data were analyzed
with FACSDIA (BD) and FlowJo software (Tree Star). For general ﬂow cytometry
analysis of cell surface markers, cells were cultured as described and stained as
above and sorted on a BD Fortessa. Example gating strategy is illustrated in
Supplementary Figure 8.
Mouse FACS analysis and sorting. Mice were euthanized with avertin overdose
and lungs were dissected and examined grossly for tumor formation. Tumors were
dissected from the lungs of primary mice and tumor tissue was prepared as
described2. Brieﬂy, tumors were isolated, minced, digested rotating for 1 h at 37 °C
with 2 mg/ml collagenase/dispase (Roche), and then ﬁltered twice (100 μm, and then
40 μm) after a 5 min incubation with 0.025 mg/ml DNase. Cell lines were trypsinized and then ﬁltered (40 μm). Single-cell suspensions were stained using antiCD31-APC (BD Pharmingen 551262), anti-CD45-APC (BD Pharmingen 559864),
anti-Epcam-PE-Cy7 (BioLegend 118216), anti-CD24-FITC (BD Pharmingen
553261), anti-Sca-1-APC-Cy7 (BD Pharmingen 560654), with DAPI (Sigma)
staining to visualize dead cells. All antibodies were incubated for 15–20 min at 1:100
dilutions. Cell sorting was performed with a Beckman Coulter/Cytomation MoFlo
or a BD FACS Aria, and data were analyzed with the FlowJo software (Tree Star
Inc.). Example gating strategy is illustrated in Supplementary Figure 9.
Quantitative RT-PCR. qPCR was carried out as previously described2. Cultured
cells or tissues were harvested and dissociated according to their speciﬁc protocols.
RNA was isolated using the Absolutely RNA Microprep Kit (Agilent). Complementary DNA was made using the SuperScript III Kit (Invitrogen) and analyzed
using TaqMan Assays (Applied Biosystems) with a StepOnePlus™ Real-Time PCR
System (Applied Biosystems) and software as per the manufacturer’s recommendations. Gapdh (4352339E) was used as an endogenous control for normalization.
Organoid-forming assays. For organoids derived from cultured adenocarcinoma
cells or primary tumors, dissociated single cells were re-suspended in a 1:1 ratio of
GFR Matrigel (Corning) and DMEM/F12 supplemented with 1× ITS (Corning) and
95 µl of cell mixture was plated in 6.5 mm, 0.4 µM membrane transwell plates
(CoStar). Either 1000 (cell lines) or 5000 cells (Primary cells) were plated per well.
Four hundred and ten miroliters of DMEM/F12 was plated beneath the transwell and
was refreshed every 48 h. At the end of the culture period, organoids were counted.
Tumor transplant assays. Intratracheal transplants of primary sorted tumor cells
were performed as described1,2. Mice were monitored for signs of lung tumor onset
and euthanized for gross and histological analysis upon signs of distress. Tail vein
injections were performed as previously described2, cells were re-suspended in PBS,
and mice were sacriﬁced 2 weeks after injection for analysis of lung metastasis. For
limiting dilution assays, cells were re-suspended in PBS and diluted to the
appropriate concentrations. Cell suspensions were then mixed 1:1 to Matrigel and
injected subcutaneously into immunocompromised mice as previously described2.
Mice were sacriﬁced after 3 weeks and tumors were measured and analyzed.
Western blotting. Western blotting was performed as was previously described38,
using the following antibodies and concentrations: H3K9me2 (Ab1220, Abcam,
1:1000) and histone H3 (ab1791, Abcam, 1:10,000). Uncropped scans are displayed
in Supplementary Figure 10.
Proliferation assays. Cells were plated at 500 cells per well in 24-well plates and
grown for 192 h, with media changes every 48 h and wells ﬁxed at timepoints with
10% formalin. Fixed cells were stained with Crystal violet and eluted stain was
measured for OD 600 absorbance on a Synergy Neo plate reader.
Microarray analysis. Microarray analysis was performed as previously described2.
ChIP and ChIP-seq. Treated cell lines were crosslinked with 1% formaldehyde in
PBS for 10 min at room temperature (RT), washed in 5 mg ml−1 bovine serum
albumin in PBS and then in just cold PBS, re-suspended in lysis buffer (50 mM
Tris-HCl, pH 8.1, 10 mM EDTA, 1% sodium dodecyl sulfate (SDS), 1× complete
protease inhibitors (Roche)) and sonicated with the Covaris M220 sonicator to
obtain chromatin fragment lengths of 200–500 bp judged by Bioanalyzer DNA
High Sensitivity Kit (Agilent). Fragmented chromatin was diluted in
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immunoprecipitation (IP) buffer (20 mM Tris-HCl, pH 8.1, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100) and incubated overnight at 4 °C with Protein G magnetic
beads (Dynabeads: Life Technologies) that had been pre-incubated with H3K9me2
(Abcam, ab1220, 62.5 ng/µl) or H3K9me1 (Abcam, ab8896, 62.5 ng/µl) antibodies.
Immunoprecipitates were washed six times with wash buffer (50 mM HEPES, pH
7.6, 0.5 M LiCl, 1 mM EDTA, 0.7% Na deoxycholate, 1% NP-40) and twice with TE
buffer. Immunoprecipitated (or no IP input) DNA was treated with RNase A and
proteinase K on the beads, recovered in 1% SDS and 0.1 M NaHCO3 over a period
of 5 h at 65 °C, and column puriﬁed with DNA clean and concentrator-25 (Zymo
Research). One to ten nanograms of DNA were used for the library construction
using NEBNext Ultra DNA Library Prep Kit (NEB E7370). Sequencing was performed on a NextSeq (Illumina) for 38 nucleotides from paired ends according to
the manufacturer’s instructions.
Sequenced reads were mapped to reference mouse genome build 38 (mm10),
using bowtie2 aligner. H3K27Ac-modiﬁed regions were identiﬁed using MACS
(version 1.4.2) as previously described43, with a P value cutoff of 1E−5 and with
default values for other parameters. Computer code is available upon request.
Quantitative differences of histone modiﬁcation between treated and non-treated
cell lines were analyzed using the MAnorm algorithm with a P value cutoff of 1E
−10 and >1 log 2 fold change.
Wiggle ﬁles with a 10 bp resolution for H3K9me2 and H3K27ac modiﬁcations
were generated by MACS v1.4.2 with tag shift and then rescaled to a larger of total
number of uniquely alignable sequences in two data sets. Histone modiﬁcation
proﬁles were then generated with the “heatmap” function or the SitePro module in
Cistrome analysis pipeline (http://cistrome.org/). Wiggle ﬁles were also visualized
in the Integrative Genomics Viewer44. ChIP-seq experiments were performed with
an n of four biological replicates
For ChIP-PCR, puriﬁed DNA from IPs as described using H3K9me2 (Ab1220,
Abcam), histone H3 (ab1791, Abcam), or IgG antibodies and input DNA was
ampliﬁed using the SYBR Green (Applied Biosystems) with a StepOnePlus™ RealTime PCR System (Applied Biosystems) and software as per the manufacturer’s
recommendations. The primer sequences used were as follows: Gapdh TSS—FWD,
5′-CTC TCT TTG GAC CCG CCT CAT TT-3′ and REV, 5′-GAG TCC TAT CCT
GGG AAC CAT CAC-3′; Sca-1 TSS—FWD, 5′-TAA CT TTT CCA GGC CAT
CAT-3′ and REV, 5′-GTT CCT CCC CAA CTG CTA TAA-3′; Mmp10 TSS—
FWD, 5′-TGA CCT AAA CAC CGA CTC CCT-3′ and REV, 5′-AGG ATG GCT
AGT GGC TCC AT-3′.
RNA-sequencing. RNA-seq was performed by the Molecular Biology Core
Facilities at the Dana-Farber Cancer Institute. RNA libraries were prepared using
Illumina TruSeq Stranded mRNA Sample Preparation Kits from 500 ng of puriﬁed
total RNA according to the manufacturer’s protocol. The resultant dsDNA libraries
were quantiﬁed by Qubit ﬂuorometer, Agilent TapeStation 2200, and quantitative
reverse transcription PCR using the Kapa Biosystems Library Quantiﬁcation Kit
according to the manufacturer’s protocols. Uniquely indexed libraries were pooled
in equimolar ratios and sequenced on a single Illumina NextSeq500 run with
single-end 75 bp reads by the Dana-Farber Cancer Institute Molecular Biology
Core Facilities.
Sequenced reads were aligned to the UCSC mm9 reference genome assembly
and gene counts were quantiﬁed using STAR (v2.5.1b)45. Differential gene
expression testing was performed by DESeq2 (v1.10.1)46 and normalized read
counts (RPKM) were calculated using cufﬂinks (v2.2.1)47. RNA-seq analysis was
performed using the VIPER snakemake pipeline (https://bitbucket.org/cfce/viper/).
Immunoﬂuorescence and immunohistochemistry. Immunoﬂuorescence of
tumor sections was performed as previously described2, with antibodies for proSPC (1:200, Santa Cruz), G9a (ab185050, Abcam, 1:200), Notch3 (5276S, Cell
Signaling, 1:100), Mmp10 (ab59437, Abcam, 1:100), Mmp13, (ab39012, Abcam,
1:100), and Mcpt4 (ab92368, Abcam, 1:100). Immunohistochemistry was performed as described2 with anti-Ki-67 (1:10,000, Novocastra) antibodies and
developed using Vectastain Elite ABC Kit (Vector Labs). Imaging was performed
with a Nikon 90i camera and NIS-Elements software and processed with NISElements and Adobe Photoshop.
Mice and tissues. Lox-Stop-Lox-KrasG12D;p53ﬂ/ﬂ and Lox-Stop-Lox-KrasG12D
mice48,49 were maintained in virus-free conditions in the 129 SvJae background. All
mouse experiments were approved by the BCH Animal Care and Use Committee
and by the Dana-Farber Cancer Institute Institutional Animal Care and Use
Committee, both accredited by AAALAC, and were performed in accordance with
relevant institutional and national guidelines and regulations. Lung tissue preparation was as described2 and sections were analyzed for tumors by at least two
investigators including a pathologist with expertise in murine lung cancer. Tumor
burden, the percentage of lung ﬁlled with tumor, was calculated using ImageJ to
measure total lung and tumor area from hematoxylin and eosin (H&E)-stained
parafﬁn sections from each mouse. For metastases, heart, liver, spleen, kidneys,
lymph nodes, and chest wall were also analyzed.
Kaplan–Meier analysis. Raw gene expression data from the Director’s Challenge
human lung adenocarcinoma samples50 were obtained (https://caintegrator.nci.nih.

gov/caintegrator/). Probe intensities from the Affymetrix U133A platform used in
these studies were normalized and modeled using the dChip software51 (http://
biosun1.harvard.edu/complab/dchip). Kaplan–Meier survival analyses were
implemented after the samples were hierarchically clustered based on EHMT2
(G9a), KMD3A, EHMT1 (Glp), or PHF8 expression. Survival differences between
the two risk groups were assessed using the Mantel–Cox log-rank test.
Cell viability assays. Cell lines were dissociated, counted, and plated at 3000 cells
per well in 96-well plates with drug concentrations of the following doses: JIB-04—
0, 1, 3, 10, 30, 100, 300, and 1000 nM; Pemetrexed—0, 1, 10, 100, 300, 1000, 3000,
and 10,000 nM. Edge wells were ﬁlled with PBS. Fresh media and drug were added
after 48 h. After 96 h, cells were ﬁxed with 10% formalin. Fixed cells were stained
with Crystal violet and eluted stain was measured for OD 600 absorbance on a
Synergy Neo plate reader. Results from independent biological replicate experiments were input into the GraphPad Prism software to extrapolate IC50 and s.e.m.
of IC50 for a given cell line using the nonlinear regression analysis of log(inhibitor)
vs. normalized response with a variable slope.
Invasion and migration assays. Invasion and migration assays were performed
with 24-well transwell plates according to the manufacturer’s instructions (Corning). Brieﬂy, cells were serum-starved overnight, harvested with Accutase (Millipore), and counted. The bottom chambers of transwells were ﬁlled with 700 μl
serum-free media or serum, and 30,000 cells per well were plated in triplicate in
100 μl serum-free media in the top chambers. After a 24-h incubation, nonmigratory cells were removed with a cotton swab, and the migratory cells were
ﬁxed with formalin and stained with DAPI. The number of DAPI+ cells were
counted and the average number of cells invading or migrating was calculated.
Mmp activity assay. The Mmp activity assay (ab112126, Abcam) was used as per
the manufacturer’s instructions. Brieﬂy, a 70% conﬂuent 10 cm plate of cells was
washed with PBS and scraped off in 1 ml 0.5% Triton X in PBS. Cell lysate was
incubated in ice for 15 min with occasional inversions, then centrifuged at 10,000
rpm at 4 °C for 10 min. The supernatant was separated and used in the protocol as
instructed. Mmps were activated for 40 min at 37 °C and ﬂuorescence was read on
a Synergy Neo plate reader.
Treatment and MRI of orthotopic allograft mouse models. Allograft of lung
adenocarcinoma cells was performed as previously described. Tumor bearing mice
were randomized into cohorts treated either with vehicle (Kolliphor-EL) or 55 mg/
kg JIB-04 3× per week for 7 weeks. The mice were imaged by magnetic resonance
imaging biweekly to determine the tumor volume during the respective treatments
as described previously in a non-blinded fashion52. The tumor burden volume and
quantiﬁcation were reconstructed on the 3D slicer software (http://www.slicer.org).
Imaging was performed with a Nikon 90i camera and NIS-Elements software and
processed with NIS-Elements and Adobe Photoshop.
Statistics. The tests used to determine statistical signiﬁcance are quoted in the
appropriate ﬁgure legend. P values are quoted either within the text or when
indicated in the ﬁgure itself, and P values <0.05 were considered signiﬁcant. When
comparing sets of continuous data from different animals, the
Kolmogorov–Smirnov test for normalcy was used to determine if a parametric or
non-parametric test was required, except where indicated, all tests were two tailed.

Data availability
Data are available upon reasonable request. The ChIP-seq data and RNA-seq that
support the ﬁndings of this study have been deposited in NCBI’s Gene Expression
Omnibus and are accessible through GEO Series accession numbers GSE100455
and GSE120073. Correspondence and requests for materials should be addressed to
C.F.K.
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